Despite the soundness of Gencor Industries' operations, the company is trading close to NCAV per share. Click here to read ...
Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1- 2,3, EMBRACE, for potent ...
Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth- -Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results